Core Viewpoint - The company announced the withdrawal of the drug registration application for "Chai Huang Li Dan Capsule" by its wholly-owned subsidiary, Beijing Yiling Pharmaceutical Co., Ltd, as per the notification from the National Medical Products Administration [1][2]. Group 1: Drug Registration Update - Beijing Yiling received approval to withdraw the registration application for "Chai Huang Li Dan Capsule," an innovative traditional Chinese medicine developed by the company [1]. - The capsule is intended for treating chronic cholecystitis with liver and gallbladder damp-heat, and related gastrointestinal symptoms [1]. - The new drug registration application was initially accepted by the National Medical Products Administration in June 2024 [1]. Group 2: Future Actions and Impact - Beijing Yiling will enhance the registration materials according to the latest requirements from the National Medical Products Administration and will resubmit the application promptly [2]. - The withdrawal of the registration application is not expected to have a significant impact on the company's current and future operations and performance [2]. - The company emphasizes the importance of drug research and development while managing R&D costs, acknowledging the high risks and long cycles associated with drug development [2].
石家庄以岭药业股份有限公司 关于全资子公司药品注册申请进展的公 告